Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)
Authors:
- 20 September 2022
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 97 (S2) , S19-S25
Abstract
As patients continue to live longer with chronic lymphocytic leukemia, it has become evident that there is an unmet treatment need for patients who have progressed on multiple lines of therapy. In this article, we attempt to define the “double refractory” patient as resistant to both Bruton's tyrosine kinase inhibitors (BTKi) and venetoclax for which prognosis is poor and there remains no standard of care. We further examine the mechanism of resistance to these targeted agents and discuss the current landscape for managing this patient population. Finally, we explore data supporting promising new agents, including non‐covalent BTKi, chimeric antigen receptor T cells, and additional classes of agents currently in development.Keywords
Funding Information
- Norges Forskningsråd (322898)
This publication has 39 references indexed in Scilit:
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaCancer Discovery, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLNew England Journal of Medicine, 2018
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformationCancer, 2018
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2018
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisHaematologica, 2018
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2018
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2015
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibNew England Journal of Medicine, 2014
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014